# EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

> **NCT04998604** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 360 (actual)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps
- Asthma

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Omalizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04998604
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-27
- **Primary completion:** 2024-10-16
- **Final completion:** 2024-12-27
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2025-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04998604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04998604, "EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04998604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*